Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures
Opdivo's Phase III disappointment in first-line non-small cell lung cancer (NSCLC) is not the end of the world for Bristol-Myers Squibb, according to Datamonitor Healthcare analyst Dustin Phan. It also may not be the last surprise in a field with so many contenders and so many ongoing trials, as data from Pharmaprojects shows.
You may also be interested in...
With positive overall survival data from the Phase III OAK trial of Tecentriq in non-small cell lung cancer, Roche enters the top flight of immuno-oncology companies alongside Merck and Bristol-Myers Squibb.
When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.